This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugano, M. Articles by Bankert, R. B. Search for Related Content PubMed PubMed Citation Articles by Sugano, M. Articles by Bankert, R. B.

Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice¹

Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263 [M. S., N. K. E., S. J. Y., F-A. C., R. B. B.], and Alza Corporation, Mountain View, California 94025 [J. H., S. K. H.]

ß₁ integrins, expressed on the cell surface of human non-small cell lung carcinomas, are used here as a target for the selective delivery of anti-cancer drug-loaded liposomes. Fab' fragments of a monoclonal antibody specific for human ß₁ integrins were conjugated to sterically stabilized liposomes. Confocal microscopy of ß₁ integrin-positive lung tumor cells incubated with fluorescently labeled anti-ß₁ Fab immunoliposomes revealed a tumor-specific binding and efficient internalization of the liposomes into the tumor cells. The ability of these liposomes to deliver cytotoxic drugs to the tumor and kill these cells was demonstrated in vitro by incubating tumor cells with doxorubicin-loaded anti-ß₁ Fab' immunoliposomes. The drug-loaded immunoliposomes were >30-fold more cytotoxic to the tumor cells than drug-loaded liposomes without antibody, nonspecific Fab' control immunoliposomes with drug or immunoliposomes without drug. The therapeutic efficacy of doxorubicin-loaded immunoliposomes was also evaluated in a metastatic human lung tumor xenograft/severe combined immunodeficient (SCID) mouse model. SCID mice that received i.v. injections of human lung tumor cells developed primary tumor nodules in the lung that subsequently metastasized to the liver and adrenal gland. Treatment of SCID mice bearing established lung tumor xenografts with doxorubicin-loaded anti-ß₁ Fab immunoliposomes resulted in a significant suppression of tumor growth (monitored periodically by quantifying serum levels of a tumor marker), whereas tumors grew progressively in mice treated with control formulations. In addition to suppressing the growth of the primary lung tumor nodules, the immunoliposomes prevented the metastatic spread of the tumor to the liver and adrenal glands and increased the median survival time of the tumor-bearing mice. We conclude that Fab' immunoliposomes directed to tumor-associated integrins represent a potentially viable approach clinically for the selective delivery of drugs to solid tumors and may be useful in preventing the metastatic spread of lung cancer.

This article has been cited by other articles:

				X. Wang, L. Yang, Z. Chen, and D. M. Shin Application of Nanotechnology in Cancer Therapy and Imaging CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110. [Abstract] [Full Text] [PDF]

				S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther., November 1, 2007; 6(11): 3019 - 3027. [Abstract] [Full Text] [PDF]

				M. Mikawa, H. Wang, L. Guo, R. Liu, J. Marik, Y. Takada, K. Lam, and D. Lau Novel peptide ligands for integrin {alpha}4{beta}1 overexpressed in cancer cells Mol. Cancer Ther., October 1, 2004; 3(10): 1329 - 1334. [Abstract] [Full Text] [PDF]

				P. Sapra and T. M. Allen Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes Clin. Cancer Res., April 1, 2004; 10(7): 2530 - 2537. [Abstract] [Full Text] [PDF]

				P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]

				F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF]

				P. Sapra and T. M. Allen Internalizing Antibodies Are Necessary for Improved Therapeutic Efficacy of Antibody-targeted Liposomal Drugs Cancer Res., December 15, 2002; 62(24): 7190 - 7194. [Abstract] [Full Text] [PDF]

				C. M. Lee, T. Tanaka, T. Murai, M. Kondo, J. Kimura, W. Su, T. Kitagawa, T. Ito, H. Matsuda, and M. Miyasaka Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo Cancer Res., August 1, 2002; 62(15): 4282 - 4288. [Abstract] [Full Text] [PDF]

				E. Waelti, N. Wegmann, R. Schwaninger, A. Wetterwald, C. Wingenfeld, B. Rothen-Rutishauser, and C. D. Gimmi Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy Cancer Res., January 1, 2002; 62(2): 437 - 444. [Abstract] [Full Text] [PDF]